Recently, Yichang Humanwell Pharmaceutical, a subsidiary of Humanwell Pharmaceutical, received the approval number from the U.S. Food and Drug Administration (FDA) for Metformin Hydrochloride Sustained Release Tablets, which indicated that Yichang Humanwell Pharmaceutical Co., LTD was qualified to sell the product in the U.S. market.

　　Metformin Hydrochloride Sustained Release Tablets are used help diabetes Type 2 diabetic patients who are not satisfied with diet control alone to improve their glycemic control. Yichang Humanwell Pharmaceutical Co., LTD submitted an ANDA application for Metformin Hydrochloride Sustained Release Tablets in 2017, with a total investment of about 5 million RMB in research and development. Obtaining the approval number from the U.S. FDA will have a positive impact on the company’s development of the U. S. generic drug market. And the company will continue to promote the preparation of the product in the U. S. market. (Correspondent Chen Ran)